Jakeccc
Long

If you've been waiting to get long REGN, now is the time.

NASDAQ:REGN   REGENERON PHARMACEUTICALS INC
46 0 2
It got beaten so badly because of some analyst's note saying that REGN's blockbuster eye drug Eylea has been replaced by cheaper rival drugs. First, it was only rumored to be "10%" of total patients, secondly, its rheumatoid arthritis drug "sarilumab" that is under development with Sanofi             is showing promising signs and is now in phase 3. Overall, reaction is a little overblown IMO             , we can expect a bounce from here.
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out